Rezdiffra (Resmetirom) Cost in Rhode Island 2026

Madrigal Pharmaceuticals markets resmetirom as Rezdiffra, a once-daily oral medication that selectively activates thyroid hormone receptor beta. In March 2024, the FDA granted resmetirom accelerated approval to treat moderate-to-advanced liver fibrosis (stages F2-F3) in adults with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH), as an adjunct to diet and lifestyle modifications. This remains resmetirom's sole FDA-approved use, with no compounded or generic formulations currently authorized by the FDA.

The direct answer for a Rhode Island reader: the specific dollar amount you will pay depends on which insurer you have, whether your plan places Rezdiffra on a specialty tier requiring prior authorization, and whether you qualify for manufacturer copay assistance. The manufacturer's published list price has been widely reported in the low thousands of dollars per month since launch, but insurer tier placement, Rhode Island Medicaid prior-authorization turnaround, and specific out-of-pocket ranges change often enough that they need to be confirmed at the point of care rather than taken from any article, including this one.

What is established, what is plausible, and what is not established

Established: Rezdiffra has FDA accelerated approval for MASH with F2-F3 fibrosis, based on the phase 3 trial that supported approval, which reported that a meaningfully larger share of resmetirom-treated patients achieved NASH resolution and fibrosis improvement at about one year compared with placebo. The FDA's accelerated approval pathway requires a confirmatory trial to verify clinical benefit, meaning the long-term outcome data (effect on liver-related death, transplant, or decompensation) is not yet final, as is standard for drugs approved under this pathway.

Plausible but not locally confirmed: That Rhode Island Medicaid and the major commercial insurers operating in the state require prior authorization with fibrosis-stage documentation is consistent with how specialty drugs are typically handled, but the exact PA criteria, tier number, copay range, and processing time for any specific Rhode Island plan in 2026 are not confirmed by a source available to this article and must be checked directly with the plan.

Not established here: Any specific dollar figure for Rhode Island cash-pay pricing, any named insurer's exact tier placement, any stated number of in-state pharmacies, and any specific prior-authorization turnaround time. These would need to come from the insurer's current provider bulletin, the state Medicaid pharmacy program, or a pharmacy price check on the day of fill, not from a national reference article.

The compact answer

Rezdiffra (resmetirom) is FDA-approved only for adults with biopsy- or noninvasive-testing-confirmed MASH and stage F2-F3 fibrosis; it has no approved generic or compounded equivalent, and its list price has been reported in the low thousands of dollars monthly since its March 2024 approval. Rhode Island Medicaid and commercial insurers in the state are expected to require prior authorization documenting fibrosis stage, similar to other specialty-tier drugs, but the specific tier, copay amount, and approval timeline vary by plan and change over time, so a reader should confirm current terms directly with their insurer or the Rhode Island Medicaid pharmacy program before assuming a cost figure applies to them.

Why the list price alone will not tell you what you pay

Manufacturers set a list price, but almost no patient with insurance pays that amount. What determines actual out-of-pocket cost is: whether the plan covers the drug at all, what specialty tier it sits on, whether a deductible must be met first, and whether the patient qualifies for a manufacturer copay card. None of those four variables are fixed nationally, and none can be answered from a general reference page. A Rhode Island Medicaid enrollee, a person with a BCBSRI commercial plan, and a self-pay patient at a compounding pharmacy are effectively answering three different cost questions, not one.

Rhode Island Medicaid: what is reasonable to expect

State Medicaid programs typically manage specialty drugs like Rezdiffra through a preferred drug list with prior authorization, often requiring documentation of the FDA-labeled population (fibrosis stage F2-F3, confirmed by biopsy or a validated noninvasive test such as FibroScan, FIB-4, or ELF score) and evidence that lifestyle intervention was attempted first. This pattern is consistent with the drug's FDA label population and with how state Medicaid programs generally handle newly approved specialty therapies, but the specific managed-care organizations administering Rhode Island Medicaid pharmacy benefits, their exact PA form requirements, and current copay amounts should be confirmed directly with the Rhode Island Executive Office of Health and Human Services or the enrollee's Medicaid managed care plan, since these details are updated periodically and were not independently verified for this article.

Commercial insurance in Rhode Island: the honest picture

Commercial insurers generally place newly approved specialty drugs like Rezdiffra on a high specialty tier with prior authorization criteria that mirror the FDA label (fibrosis stage F2-F3, prior lifestyle intervention, sometimes a specialist prescriber requirement). Whether a specific Rhode Island insurer currently requires a hepatologist or gastroenterologist referral, what its exact tier number is, or what coinsurance percentage applies is plan-specific and time-sensitive information that a national article cannot responsibly assert without a current source. Readers should request a benefits investigation from their insurer's specialty pharmacy department, which will state the current tier, copay or coinsurance amount, and any step-therapy requirement in writing.

Manufacturer copay assistance

Madrigal Pharmaceuticals has offered a copay assistance program for commercially insured patients since launch. Copay assistance programs of this type typically exclude patients enrolled in government insurance (Medicare, Medicaid, TRICARE) under federal anti-kickback rules, require an active commercial plan, and have an annual cap that resets each calendar year. The exact current cap, enrollment process, and any 2026 program changes should be confirmed directly through the manufacturer's patient support program rather than assumed from a prior year's terms, since manufacturer assistance programs change without public notice.

Compounded resmetirom: what is regulated fact and what is not

Federal law distinguishes 503A pharmacies, which compound patient-specific prescriptions under state board of pharmacy oversight, from 503B outsourcing facilities, which compound at scale under closer FDA oversight. The FDA has stated that compounding an essential copy of a commercially available FDA-approved drug is generally restricted, with narrow exceptions such as a documented clinical need for a different strength or formulation for a specific patient (FDA compounding laws and policies). Compounded resmetirom has not undergone the FDA's dissolution, bioequivalence, or manufacturing review that the approved tablet underwent, so its actual absorption and effect in an individual patient is not established the way the approved product's is. Any Rhode Island-licensed 503A pharmacy compounding resmetirom would need to justify the clinical basis for a non-generic-copy formulation, and pricing at such pharmacies varies by location and is not something this article can state as a figure without direct pharmacy verification.

Telehealth prescribing

Telehealth prescribing for chronic disease management, including MASH follow-up, is broadly permitted across most states subject to the prescriber holding an active license (or an interstate compact license) in the state where the patient is located. Rhode Island has generally supported telehealth parity for specialist follow-up care, but confirming that a specific telehealth platform and prescriber meet current Rhode Island Department of Health requirements is the responsibility of the prescribing practice, not something a cost article can certify as current for 2026.

How the trial evidence frames the cost conversation

The pivotal phase 3 trial supporting the FDA's accelerated approval enrolled patients with biopsy-confirmed MASH and fibrosis and compared resmetirom against placebo over roughly one year. It reported that a meaningfully larger proportion of resmetirom-treated patients achieved NASH resolution without worsening fibrosis, and a larger proportion achieved at least one stage of fibrosis improvement, compared with placebo. Exact percentages are cited across secondary sources inconsistently; a reader or clinician who needs the precise trial numbers for a prior authorization appeal should pull them directly from the FDA-reviewed label or the published trial report rather than from this or any secondary summary, to avoid citing a misremembered figure.

Before Rezdiffra, MASH management relied on lifestyle intervention and off-label use of generic drugs such as vitamin E or pioglitazone in specific subgroups, none of which carry an FDA indication for fibrosis improvement in MASH. This context is relevant to a cost conversation because a plan's medical necessity review will typically ask whether lower-cost alternatives were tried first, which is part of why prior authorization exists rather than a formulary quirk specific to Rhode Island.

Monitoring costs beyond the drug price

The FDA label calls for baseline and periodic liver function testing, and resmetirom's mechanism as a thyroid hormone receptor beta agonist is a reason clinicians also track lipid and thyroid-related labs during treatment (FDA prescribing information, accessdata.fda.gov). Because the drug was approved under the accelerated pathway, a confirmatory outcomes trial is required to verify long-term clinical benefit; this is a standard condition of accelerated approval and does not mean the drug lacks evidence, but it does mean the full outcomes picture is still being generated. Patients should expect periodic lab work and possible FibroScan reassessment as part of ongoing treatment and PA renewal; the specific cost of that monitoring depends on the individual's insurance benefit design and is not a fixed national figure.

Background on disease burden

Fatty liver disease affects a substantial share of U.S. adults, and chronic liver disease and cirrhosis remain a recognized cause of death tracked by federal health statistics (CDC, chronic liver disease and cirrhosis). This is useful context for why insurers are building coverage pathways for MASH therapies at all, but it does not tell an individual reader what their plan will charge.

Verification checklist: what you can trust today versus what you must confirm before paying

Use this to separate facts that are stable and federally documented from facts that shift by plan, pharmacy, or month.

Stable, generally verifiable facts (check the source, not the price):

• FDA-approved indication: MASH with fibrosis stage F2-F3, confirmed via the FDA prescribing information at accessdata.fda.gov.
• Approval pathway: accelerated approval (March 2024), which requires a confirmatory trial for full outcome verification, confirm current status directly with the FDA.
• Drug class and mechanism: thyroid hormone receptor beta-selective agonist, oral, once daily.
• Regulatory distinction between 503A and 503B compounding, and the FDA's general restriction on compounding essential copies of approved drugs, confirm against the FDA compounding policy page.
• General monitoring rationale (liver panel, lipid panel, thyroid function) as reflected in the FDA label.

Date-sensitive facts you must confirm yourself before relying on them:

• Current manufacturer list price and any cash-pay price at a specific Rhode Island pharmacy this month.
• Rhode Island Medicaid's current managed care organization structure, PDL tier, and prior authorization form for Rezdiffra.
• Any specific commercial insurer's (BCBSRI, UnitedHealthcare, Cigna, Aetna, or an employer's self-insured plan) current tier placement, coinsurance percentage, and specialist-referral requirement.
• The manufacturer copay assistance program's current annual cap, eligibility rules, and enrollment process.
• Any compounding pharmacy's current license status, compounding rationale on file, and price quote.
• Current prior authorization turnaround times, which are set by the specific plan and can change without notice.

How to confirm each date-sensitive item: call the insurer's specialty pharmacy or pharmacy benefits line and ask for the current PA criteria and copay in writing; call the Rhode Island Medicaid pharmacy help desk directly; call the compounding pharmacy and ask for its Rhode Island Board of Pharmacy license number and current price; check the manufacturer's official patient support page for the current copay program terms.

When to seek care rather than manage this by phone alone

If ALT, AST, or bilirubin rise substantially after starting resmetirom, or if a patient develops jaundice, dark urine, unusual fatigue, or right upper quadrant pain, that is a reason for urgent clinical evaluation rather than a cost question. Cost and access barriers should never delay reporting new symptoms to the prescribing clinician.